Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alipogene tiparvovec

Drug Profile

Alipogene tiparvovec

Alternative Names: AMT-010; AMT-011; AMT-11; Glybera; LPL gene therapy - AMT

Latest Information Update: 14 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Developer Chiesi Farmaceutici; uniQure
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action Gene transference; Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type I
  • Discontinued Hyperlipoproteinaemia type V

Most Recent Events

  • 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
  • 22 Sep 2017 Discontinued - Phase-I/II for Hyperlipoproteinaemia type V in European Union (IM), because there have been no recent reports on development in this indication
  • 21 Sep 2017 Discontinued - Phase-II/III for Hyperlipoproteinaemia type I in Canada (IM), because not listed in uniQure pipeline, September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top